Therapy News and Research

RSS

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.

26 Feb 2010

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

AST now offers programs and services to treat children with developmental disorders

Autism Spectrum Therapies, an agency providing comprehensive autism services throughout Southern California, is expanding its services to include speech and language programs and occupational therapy, in addition to behavior therapy. The focus of the new services will be early intervention for children from infancy to age three and developmental catch-up for young children who have fallen behind in any developmental area.

26 Feb 2010

Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB

Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced mortality rates by 56 percent in a randomized clinical trial of 642 patients co-infected with HIV and tuberculosis. The study, which provides further impetus for the integration of TB and HIV services, lays to rest the controversy on whether co-infected patients should initiate ART during or after TB treatment.

26 Feb 2010

Guidant conceals defibrillator safety problems from FDA, is charged with criminal violations

Medical device manufacturer Guidant LLC, a wholly-owned subsidiary of Boston Scientific Corporation, was charged today with criminal violations of the Federal Food, Drug, and Cosmetic Act related to safety problems with some of its implantable defibrillators. Guidant LLC formerly did business as Guidant Corporation. The Justice Department filed the criminal information today in connection with an agreement with Guidant to resolve the charges. A formal guilty plea agreement is expected to be filed with the court at a later date.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

Ferring Pharmaceuticals, GSN sign agreement to test Parental Support technology

Ferring Pharmaceuticals and Gene Security Network announced that they have signed an agreement to conduct a clinical trial of GSN's advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™.

26 Feb 2010

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers - the most common cancer in Australian men.

25 Feb 2010

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

25 Feb 2010

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Translational Regenerative Medicine Forum in Winston-Salem

A spray-on skin product and an injectable cell therapy for heart attack patients are among 17 regenerative medicine technologies that will be showcased during the Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.

25 Feb 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Family violence survivors: Enhancing resilience a promising therapy

Thousands of men, women and children experience family violence each year, according to the U.S. Department of Justice. Traditionally, therapy for violence survivors has predominantly focused on evaluating their trauma and pain. In contrast, a University of Missouri researcher broadens the therapeutic focus to empower survivors through highlighting their resilience, resourcefulness, and ability to overcome adversity.

25 Feb 2010

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

The Government of Quebec's Ministère de la santé et des services sociaux has approved the addition of Revlimid(R) (lenalidomide) to the Province's Drug Formulary as a third-line therapy for multiple myeloma patients. The cost of the drug will be reimbursed under the Province's medicare system.

25 Feb 2010

Upcoming web conference focuses on Next Generation Ultrasound Market in Europe

Exposure to radiation from imaging equipment is constantly subjected to scrutiny from regulatory authorities. Ultrasound poses no radiation threat and is constantly further developed to accentuate primary and secondary diagnosis. The next wave in ultrasound technology will witness advancements in Elastography and Contrast Enhanced Ultrasound (CEUS) for diagnosis.

25 Feb 2010

Therapy News and Research

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

AST now offers programs and services to treat children with developmental disorders

Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB

Guidant conceals defibrillator safety problems from FDA, is charged with criminal violations

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Ferring Pharmaceuticals, GSN sign agreement to test Parental Support technology

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Study demonstrates Prochymal treamtent is safe for cardiac patients

Translational Regenerative Medicine Forum in Winston-Salem

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Family violence survivors: Enhancing resilience a promising therapy

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

Upcoming web conference focuses on Next Generation Ultrasound Market in Europe

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News